Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: Kinetic modeling and test-retest study in human brain

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1285-1293

  Van Laere, Koen ^a   Ahmad, Rawaha U ^a   Hudyana, Hendra ^a   Dubois, Kristof ^b   Schmidt, Mark E ^b   Celen, Sofie ^c   Bormans, Guy ^c   Koole, Michel ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

18F; PDE10A; PET; Phosphodiesterase; Radioligand

Indexed keywords

FLUORODEOXYGLUCOSE F 18; JNJ 42259152; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; TRACER; UNCLASSIFIED DRUG; 2 ((4 (1 (2 FLUOROETHYL) 4 (4 PYRIDINYL) 1H PYRAZOL 3 YL)PHENOXY)METHYL) 3,5 DIMETHYLPYRIDINE; 2-((4-(1-(2-FLUOROETHYL)-4-(4-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENOXY)METHYL)-3,5-DIMETHYLPYRIDINE; DIAGNOSTIC AGENT; FLUORINE 18; PDE10A PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RADIOLIGAND;

ADULT; AGED; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; CORPUS STRIATUM; DISTRIBUTION VOLUME; FEMALE; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NEUROIMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; REPRODUCIBILITY; SUBSTANTIA NIGRA; THALAMUS; TISSUE DISTRIBUTION; VOLUNTEER; BIOLOGICAL MODEL; BLOOD; BRAIN; CLINICAL TRIAL; KINETICS; METABOLISM; MIDDLE AGED; PDE10A; PET; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

18F; PDE10A; PET; PHOSPHODIESTERASE; RADIOLIGAND;

ADULT; AGED; BIOLOGICAL TRANSPORT; BRAIN; FEMALE; HUMANS; KINETICS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHOSPHORIC DIESTER HYDROLASES; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; PYRIDINES; RADIOACTIVE TRACERS; REPRODUCIBILITY OF RESULTS; TISSUE DISTRIBUTION;

EID: 84881404106     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.118679     Document Type: Article

References (21)

1. Seeger TF, Bartlett B, Coskran TM, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003;985:113-126.
2. 11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorg Med Chem. 2011;19:1666-1673.
3. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488-520.
4. Fujishige K, Kotera J, Omori K. Striatum-and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem. 1999; 266:1118-1127.
5. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 2007;30:228-235.
6. Nishi A, Kuroiwa M, Miller DB, et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci. 2008;28: 10460-10471.
7. Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther. 2008;325:681-690.
8. Grauer SM, Pulito VL, Navarra RL, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009;331:574-590.
9. Siuciak JA, McCarthy SA, Chapin DS, et al. Genetic deletion of the striatumenriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology. 2006;51:374-385.
10. Hebb AL, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience. 2004;123:967-981.
11. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov. 2006;5:660-670.
12. 11C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. Nucl Med Biol. 2011;38:875-884.
13. Tu Z, Xu J, Jones LA, Li S, Mach RH. Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nucl Med Biol. 2010;37:509-516.
14. Celen S, Koole M, De Angelis M, et al. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med. 2010;51:1584-1591.
15. Andrés JI, De Angelis M, Alcazar J, et al. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging. J Med Chem. 2011;54:5820-5835.
16. Van Laere K, Ahmad RU, Hudyana H, et al. Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. Eur J Nucl Med Mol Imaging. 2013;40:254-261.
17. 18F-]JNJ-422J9152 as a PET tracer for PDE10A. Neuroimage. In press.
18. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27:1533-1539.
19. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
20. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23: 1096-1112.
21. 18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314-319.